|
1
|
Chang K, Pastan I and Willingham MC:
Isolation and characterization of a monoclonal antibody, K1,
reactive with ovarian cancers and normal mesothelium. Int J Cancer.
50:373–381. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Argani P, Iacobuzio-Donahue C, Ryu B,
Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E,
Yeo CJ, et al: Mesothelin is overexpressed in the vast majority of
ductal adenocarcinomas of the pancreas: Identification of a new
pancreatic cancer marker by serial analysis of gene expression
(SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
|
|
3
|
Ordonez NG: Value of mesothelin
immunostaining in the diagnosis of mesothelioma. Mod Pathol.
16:192–197. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Einama T, Kamachi H, Nishihara H, Homma S,
Kanno H, Takahashi K, Sasaki A, Tahara M, Okada K, Muraoka S, et
al: Co-expression of mesothelin and CA125 correlates with
unfavorable patient outcome in pancreatic ductal adenocarcinoma.
Pancreas. 40:1276–1282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang K and Pastan I: Molecular cloning of
mesothelin, a differentiation antigen present on mesothelium,
mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA.
93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hassan R, Bera T and Pastan I: Mesothelin:
A new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li M, Bharadwaj U, Zhang R, Zhang S, Mu H,
Fisher WE, Brunicardi FC, Chen S and Yao Q: Mesothelin is a
malignant factor and therapeutic vaccine target for pancreatic
cancer. Mol Cancer Ther. 7:286–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shiraishi T, Shinto E, Mochizuki S, Tsuda
H, Kajiwara Y, Okamoto K, Einama T, Hase K and Ueno H: Mesothelin
expression has prognostic value in stage II/III colorectal cancer.
Virchows Arch. 474:297–307. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Einama T, Homma S, Kamachi H, Kawamat F,
Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H,
Matsuno Y, et al: Luminal membrane expression of mesothelin is a
prominent poor prognostic factor for gastric cancer. Br J Cancer.
107:137–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiraishi T, Shinto E, Nearchou IP, Tsuda
H, Kajiwara Y, Einama T, Caie PD, Kishi Y and Ueno H: Prognostic
significance of mesothelin expression in colorectal cancer
disclosed by area-specific four-point tissue microarrays. Virchows
Arch. Feb 27–2020.(Epub ahead of print). doi:
10.1007/s00428-020-02775-y. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Niu Z, Zhang L, Liu X, Wang X, Li
F and Wang Y: Clinicopathological significance of mesothelin
expression in invasive breast cancer. J Int Med Res. 40:909–916.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parinyanitikul N, Blumenschein GR, Wu Y,
Lei X, Chavez-Macgregor M, Smart M and Gonzalez-Angulo AM:
Mesothelin expression and survival outcomes in triple receptor
negative breast cancer. Clin Breast Cancer. 13:378–384. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y,
Varol U, Yildiz I, Alacacioglu A, Akyol M, Demir L, Dirican A and
Yildiz Y: Prognostic value of mesothelin expression in patients
with triple negative and HER2-positive breast cancers. Biomed
Pharmacother. 70:190–195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tchou J, Wang LC, Selven B, Zhang H,
Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM,
June CH and Zhang PJ: Mesothelin, a novel immunotherapy target for
triple negative breast cancer. Breast Cancer Res Treat.
133:799–804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsuda H, Akiyama F, Kurosumi M, Sakamoto G
and Watanabe T: Establishment of histological criteria for
high-risk node-negative breast carcinoma for a multi-institutional
randomized clinical trial of adjuvant therapy. Japan National
Surgical Adjuvant Study of Breast Cancer (NSAS-BC) pathology
section. Jpn J Clin Oncol. 28:486–491. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: Recommendations from the
international Ki67 in Breast Cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curigliano G, Burstein HJ, Winer EP, Gnant
M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn
HJ, et al: De-escalating and escalating treatments for early-stage
breast cancer: The St. Gallen international expert consensus
conference on the primary therapy of early breast cancer 2017. Ann
Oncol. 30:11812019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang M, Li A, Sun G, Mbuagbaw L, Reid S,
Lovrics PJ and Thabane L: Association between mesothelin expression
and survival outcomes in patients with triple-negative breast
cancer: A protocol for a systematic review. Syst Rev. 5:1332016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan AR and Swain SM: Therapeutic
strategies for triple-negative breast cancer. Cancer J. 14:343–351.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawamata F, Kamachi H, Einama T, Homma S,
Tahara M, Miyazaki M, Tanaka S, Kamiyama T, Nishihara H, Taketomi A
and Todo S: Intracellular localization of mesothelin predicts
patient prognosis of extrahepatic bile duct cancer. Int J Oncol.
41:2109–2118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mizukami T, Kamachi H, Fujii Y, Matsuzawa
F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y and Taketomi A:
The anti-mesothelin monoclonal antibody amatuximab enhances the
anti-tumor effect of gemcitabine against mesothelin-high expressing
pancreatic cancer cells in a peritoneal metastasis mouse model.
Oncotarget. 9:33844–33852. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujisaka Y, Kurata T, Tanaka K, Kudo T,
Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C
and Nakagawa K: Phase I study of amatuximab, a novel monoclonal
antibody to mesothelin, in Japanese patients with advanced solid
tumors. Invest New Drugs. 33:380–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
